Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555 PHASE4 COMPLETED

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

Details

Lead sponsor	Genentech, Inc.
Phase	PHASE4
Status	COMPLETED
Enrolment	179
Start date	Thu Jul 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Nov 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Multiple Sclerosis, Relapsing

Interventions

• Ocrelizumab

Countries

Kenya, United States, Puerto Rico